Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
Journal for ImmunoTherapy of Cancer · 2024-02 · 12 (2) · e008735
DOI: 10.1136/jitc-2023-008735 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 29.02.2024. Verfasst von Allison Betof Warner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University School of Medicine, Stanford, California, USA schoenfa@mskcc.org allison.betof@stanford.edu. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Melanoma. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Iovance Biotherapeutics.
Abstract (Originalsprache)
Adoptive cell therapy with autologous, ex vivo-expanded, tumor-infiltrating lymphocytes (TILs) is being investigated for treatment of solid tumors and has shown robust responses in clinical trials. Based on the encouraging efficacy, tolerable safety profile, and advancements in a central manufacturing process, lifileucel is now the first US Food and Drug Administration (FDA)-approved TIL cell therapy product. To this end, treatment management and delivery practice guidance is needed to ensure successful integration of this modality into clinical care. This review includes clinical and toxicity management guidelines pertaining to the TIL cell therapy regimen prepared by the TIL Working Group, composed of internationally recognized hematologists and oncologists with expertize in TIL cell therapy, and relates to patient care and operational aspects. Expert consensus recommendations for patient management, including patient eligibility, screening tests, and clinical and toxicity management with TIL cell therapy, including tumor tissue procurement surgery, non-myeloablative lymphodepletion, TIL infusion, and IL-2 administration, are discussed in the context of potential standard of care TIL use. These recommendations provide practical guidelines for optimal clinical management during administration of the TIL cell therapy regimen, and recognition of subsequent management of toxicities. These guidelines are focused on multidisciplinary teams of physicians, nurses, and stakeholders involved in the care of these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stanford University School of Medicine, Stanford, California, USA schoenfa@mskcc.org allison.betof@stanford.edu.
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, USA.
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
- Medical Oncology, Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands.
ORCID-Profile: Allison Betof Warner, John Haanen, Igor Puzanov, Amod Sarnaik, Adam J Schoenfeld
Förderung
- NCI NIH HHS
- Iovance Biotherapeutics
Zitieren
APA
Betof Warner, A., Hamid, O., Komanduri, K., Amaria, R., Butler, M. O., Haanen, J., Nikiforow, S., Puzanov, I., Sarnaik, A., Bishop, M. R., & Schoenfeld, A. J. (2024). Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. Journal for ImmunoTherapy of Cancer, 12(2), e008735. https://doi.org/10.1136/jitc-2023-008735
Vancouver
Betof Warner A, Hamid O, Komanduri K, Amaria R, Butler MO, Haanen J, et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. Journal for ImmunoTherapy of Cancer. 2024;12(2):e008735. doi:10.1136/jitc-2023-008735
BibTeX
@article{BetofWarner2024,
author = {Betof Warner, Allison and Hamid, Omid and Komanduri, Krishna and Amaria, Rodabe and Butler, Marcus O and Haanen, John and Nikiforow, Sarah and Puzanov, Igor and Sarnaik, Amod and Bishop, Michael R and Schoenfeld, Adam J},
title = {Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {2},
pages = {e008735},
doi = {10.1136/jitc-2023-008735}
}
EUVIMED